NCT04003246 2025-03-21
Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
University of Texas Southwestern Medical Center
OHSU Knight Cancer Institute
Mayo Clinic